News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Sanofi to utilise Scribe's CRISPR platform to develop cancer cell therapies
September 27, 2022
FirstWord Pharma
Read Now
Press Release
Sanofi to utilise Scribe's CRISPR platform to develop cancer cell therapies
September 27, 2022
FirstWord Pharma
Read Now
News
Sanofi and Jennifer Doudna-Founded Scribe Ink $1B CRISPR Cell Therapy Deal
September 27, 2022
BioSpace
Read Now
Press Release
Sanofi and Jennifer Doudna-Founded Scribe Ink $1B CRISPR Cell Therapy Deal
September 27, 2022
BioSpace
Read Now
News
Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story
September 27, 2022
Fierce Biotech
Read Now
Press Release
Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story
September 27, 2022
Fierce Biotech
Read Now
News
CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives
August 12, 2022
Endpoints News
Read Now
Press Release
CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives
August 12, 2022
Endpoints News
Read Now